Rafael de Cabo
Dr. Rafael de Cabo is a senior researcher at the National Institute on Aging, with over two decades of experience studying the effects of metformin on aging in animal models. His work has explored the drug's potential to extend lifespan and its implications for treating age-related diseases, making him a key figure in the ongoing research into the intersection of diabetes management and longevity.
Not in the pool (under ¢1).
Recent news mentions
Rafael de Cabo presented new data regarding Taurin's levels in the body as it relates to aging.
Können Rapamycin und Metformin das Altern stoppen?
Switzerland· 2025-08-26
Rafael de Cabo is the head of the Translational Gerontology Department at the National Institute on Aging in Baltimore, USA, and he leads a study questioning previous results on taurine and aging.
Un estudio cuestiona el papel de la taurina para ralentizar el envejecimiento | Salud y bienestar
Spain· 2025-06-05
Dr. Rafael de Cabo's research showed that low doses of metformin extended the lifespan of healthy male mice by about 5%.
Kansere ve yaşlanmaya karşı yeni umut: ‘Mucize ilaç’ şaşkınlık yarattı… ‘Etkisi fazla, maliyeti çok az’
Turkey· 2025-05-12
Rafael de Cabo is a senior researcher studying metformin and its effects on aging at the National Institute on Aging.
Remédio popular contra o diabetes ganha fama como promotor da longevidade; veja o que a ciência diz
Liechtenstein· 2025-05-08
Rafael de Cabo is a senior researcher at the National Institute on Aging who has studied metformin in mice for over two decades.
¿La metformina puede desacelerar el envejecimiento?
Guatemala· 2025-05-07